查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466392

癌症/腫瘤分析市場：按技術、生物標記類型、癌症類型、應用分類 - 2024-2030 年全球預測

Cancer/Tumor Profiling Market by Technology (Immunoassays, In-Situ Hybridization, Mass Spectrometry), Biomarker Type (Genomic Biomarker, Protein Biomarker), Cancer Type, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症/腫瘤分析市場規模預計為107.9億美元，預計2024年將達到127.7億美元，2030年將達到359.4億美元，複合年成長率為18.74%。

癌症/腫瘤分析是一種分析腫瘤內特定蛋白質、基因和其他分子並提供有關遺傳或分子變化（例如基因突變）的資訊的測試。腫瘤分析是腫瘤學家廣泛使用的技術，用於確定患者的腫瘤途徑是否與現有的標靶治療相容。生物標記在癌症患者治療中的加速使用、對客製化癌症治療的日益偏好以及政府和國際組織對癌症診斷開發的日益關注我們正在支持癌症/腫瘤分析技術的普及。然而，癌症/腫瘤分析工具和服務的高資本投資以及生物標記的低發現核准率正在阻礙市場開拓。然而，隨著次世代定序的普及、腫瘤分析的改進以及照護現場檢測技術的擴展，預計未來幾年的使用量將激增。

主要市場統計
基準年[2023] 107.9億美元
預測年份 [2024] 127.7億美元
預測年份 [2030] 359.4億美元
複合年成長率（%） 18.74%

採用次世代定序儀(NGS) 技術研究各種癌症的基因變化

免疫檢測在癌症腫瘤分析市場的技術領域佔據主導地位，因為它們擴大應用於大規模腫瘤分析，因為它們有助於確定樣本中分析物的存在和濃度。螢光原位雜合技術原位雜合反應(FISH) 和顯色原位雜合反應(CISH)，利用固定在染色體或玻片上的標記互補 DNA 或 RNA 鏈來定位特定的 DNA 或 RNA 序列。一部分（原位）。 FISH 分析比傳統方法更省時，並且可以輕鬆檢查染色體微缺失、擴增和易位。基於質譜的研究擴大用於癌症研究，以檢測蛋白質組和代謝組的細微變化。相較之下，微陣列廣泛用於了解癌細胞的遺傳和表觀遺傳組成，並已被用來識別癌細胞中的微小遺傳變化。次世代定序儀（NGS）的發展可以有效地探索各種癌症的遺傳改變，並識別多種遺傳或表觀遺傳突變，從而產生新的生物標記物，對疾病的早期診斷有所幫助。聚合酵素鏈鎖反應(PCR) 用於檢查基因和染色體的特定變化，有助於發現和診斷遺傳狀況和疾病，例如癌症。此外，診斷影像和生化過程的技術進步能夠及早發現轉移性病變，這可能會提高癌症治療的成功率。

生物標記的類型：基因生物標記用於測量基因表現、基因功能和基因調控。

基因生物標記可稱為基因表現、基因功能和基因調控的測量，測試顯示一個人的癌症具有假定的腎小球濾過率（EGFR）基因突變，可以用 EGFR 抑制劑治療。治療方法是否正在臨床試驗中進行測試。理想的癌症生物標記可以是在患者血液或尿液中很容易檢測到的蛋白質或蛋白質片段，健康患者除外。此外，許多癌症生物標記在體內的作用不同，對治療的反應也不同。這些癌症生物標記還可以包括基因突變（變化）、基因重排、基因的額外拷貝、基因缺陷和幾種其他分子。

癌症類型：前列腺癌癌症分析用於預測建模和臨床風險分層的廣泛偏好

癌症/腫瘤分析已成為乳癌多個層面疾病管理的重要組成部分。基因檢測可識別有惡性家族病史的患者的遺傳性癌症症候群，有助於成功預防乳癌。大腸直腸癌 (CRC) 的分子分析具有提供有關癌症病理學和標靶治療的重要資訊的優點。儘管化療仍然是治療的支柱，但隨著對其異質性和分子藍圖的了解，轉移性大腸直腸癌 (mCRC) 治療的模式正在改變。可以檢測肺癌的常見基因突變，例如估計腎小球濾過率（EGFR）、RET、MET、BRAF和間變性淋巴瘤激酶（ALK），從而為患者提供標靶治療。基於基因表現(GEP) 的皮膚黑色素瘤 (CM) 分子預測測試非常敏感，並且具有預測生物學行為的潛力。此外，前列腺癌的癌症/腫瘤分析最近已成為預測建模和臨床風險分層的可靠方法。前列腺腫瘤的綜合基因組分析提供了全面的資訊和新發現，將在精準醫學的新時代提高對疾病的理解。

應用擴大使用癌症/腫瘤分析來開發精準醫學，以縮短癒合和恢復時間

癌症/腫瘤分析將透過識別治療標靶和分子生物標記、顯著改善許多常見和罕見腫瘤的結果以及個人化癌症治療來極大地推進臨床腫瘤學。癌症/腫瘤分析通常用於開發針對患者基因組成的精準醫療，並縮短癒合和恢復時間。新技術和複雜技術的應用以及生物標記的臨床應用將提升生物標記的發現和開發，並改善診斷、預後和疾病監測。研究人員正在尋求更精確、更有針對性的技術來簡化癌症治療，導致快速診斷提供者尋求高度複雜的癌症分析方法。基於基因組的預後生物標記用於預測臨床階段幾種癌症類型的預後，也可用於藥物和治療方法的開發。癌症/腫瘤分析也可用於癌症篩檢，有助於早期發現、早期管理和可能治癒癌症。此外，癌症/腫瘤分析提供了靈敏且準確的生物標記檢測，並為非侵入性疾病診斷和治療反應監測提供了可靠的方法。

區域洞察

北美、歐盟、海灣合作理事會和亞太地區已開發國家的癌症/腫瘤分析市場格局具有突出的舉措參與企業和完善的監管框架，以減輕癌症負擔，同時改善患者照護。 。隨著癌症診斷投資的不斷增加，癌症分析逐漸在世界各地的新興經濟體中受到關注。據美國癌症協會稱，預計 2023 年美國將有約 190 萬名新癌症患者被診斷出來，這增加了癌症分析的需求。在北歐和西歐國家，生物標記測試的採用率和可用性要高得多，反映出醫療保健方面的投資增加。國際市場相關人員正在與美國和歐洲國家的技術提供者合作，為癌症診斷、分析和治療方法的進步做出貢獻。此外，正在進行的宣傳活動和癌症意識計劃強調了亞洲國家進行癌症/腫瘤分析的必要性。

FPNV定位矩陣

FPNV 定位矩陣對於評估癌症/腫瘤分析市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對癌症/腫瘤分析市場中供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.癌症/腫瘤分析市場的市場規模和預測是多少？

2.在癌症/腫瘤分析市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.癌症/腫瘤分析市場的技術趨勢和法規結構是什麼？

4.癌症/腫瘤分析市場主要供應商的市場佔有率為何？

5. 進入癌症/腫瘤分析市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 在癌症患者的治療中更多地採用生物標記
      • 各國政府和國際組織為開發癌症診斷方法所做的努力
      • 人們對癌症治療中的個人化醫療越來越感興趣
    • 抑制因素
      • 對癌症/腫瘤分析設備和服務的大量資本投資
    • 機會
      • 次世代定序的出現和腫瘤分析的進展
      • 改進照護現場診斷技術以改善癌症檢測
    • 任務
      • 生物標記的發現率和核准較低
  • 市場區隔分析
    • 技術：使用次世代定序(NGS) 尋找各種癌症的基因突變
    • 生物標記的類型：基因生物標記用於測量基因表現、基因功能和基因調控。
    • 癌症類型：廣泛推薦前列腺癌的癌症分析以用於預測模型和臨床風險分層
    • 應用：在開發精準醫學中增加使用癌症/腫瘤分析來縮短癒合和恢復時間
  • 市場趨勢分析
    • 政府在癌症診斷方面的措施以及癌症/腫瘤分析解決方案的快速進展
    • 癌症發生率的上升和癌症研究的進步正在推動亞太地區對新的癌症/腫瘤分析的需求。
    • 全部區域擴大採用精準藥物和基因分析解決方案來克服癌症負擔
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章癌症/腫瘤分析市場：依技術分類

  • 免疫學測試
  • 原位雜合技術
  • 質譜
  • 微陣列
  • 次世代定序
  • 聚合酵素鏈鎖反應

第 7 章按生物標記類型分類的癌症/腫瘤分析市場

  • 基因生物標記
  • 蛋白質生物標記

第 8 章按癌症類型分類的癌症/腫瘤分析市場

  • 乳癌
  • 大腸直腸癌
  • 肺癌
  • 黑色素瘤癌症
  • 攝護腺癌

第9章癌症/腫瘤分析市場：依應用分類

  • 生物標記發現
  • 臨床應用
  • 診斷
  • 個人化醫療
  • 預言
  • 調查
  • 篩分
  • 治療和監測

第10章美洲癌症/腫瘤分析市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太癌症/腫瘤分析市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的癌症/腫瘤分析市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 安捷倫與 NCCS 簽署研究合作協議，推動新加坡亞洲常見癌症的基因組分析
    • Sophia Genetics 與安捷倫合作開發癌症分析產品
    • Point32Health 和 Foundation Medicine 擴大了晚期癌症患者全面基因組分析的範圍
    • 協同效應 Laboratories 選擇 SOPHiA GENETICS 技術用於新的癌症分析解決方案
    • Exact Sciences 在美國推出 OncoExTra 癌症治療選擇測試
    • Caris Life Sciences 籌集了 4 億美元，使總資金籌措接近 20 億美元
    • Prenetics 旗下 ACT Genomics 的 ACTOnco 獲得 FDA 批准
    • 安捷倫宣布收​​購用於癌症研究的高性能 NGS靶向序列捕獲工作流程開發商 Avida Biomed
    • Prenetics 收購 ACT Genomics
    • 羅氏首個伴同性診斷獲得 FDA核准，用於識別符合 Enhertu 資格的 HER2 低轉移性乳癌患者
    • CDC 撥款 2.15 億美元推動癌症登月目標

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-374DB5A06C7F

[199 Pages Report] The Cancer/Tumor Profiling Market size was estimated at USD 10.79 billion in 2023 and expected to reach USD 12.77 billion in 2024, at a CAGR 18.74% to reach USD 35.94 billion by 2030.

Cancer/tumor profiling is a laboratory method that analyzes specific proteins, genes, and other molecules in a tumor to provide information about any genetic or molecular changes, such as gene mutations. Tumor profiling is the technology that oncologists widely use to determine if the pathways of a patient's tumor match up with available targeted treatments. Accelerated use of biomarkers in the treatment of cancer patients and increasing preference for customized cancer treatments coupled with government and international organization's efforts to develop cancer diagnosis methods support the widespread use of cancer/tumor profiling technologies. On the other hand, high capital investment in cancer/tumor profiling tools and services and low biomarker discovery-to-approval ratio hinders market development. However, the spread of next-generation sequencing, tumor profiling improvements, and point-of-care cancer detection technology expansion is expected to surge their use in the coming years.

KEY MARKET STATISTICS
Base Year [2023] USD 10.79 billion
Estimated Year [2024] USD 12.77 billion
Forecast Year [2030] USD 35.94 billion
CAGR (%) 18.74%

Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers

Immunoassays dominate the technology segment of the cancer tumor profiling market owing to rising applications in conducting tumor profiling on a large scale, as they aid in measuring the presence and concentration of analytes in a sample. In situ hybridization (ISH), including fluorescence in-situ hybridization (FISH) and chromogenic in situ hybridization (CISH), uses labeled complementary DNA or RNA strands to localize a specific DNA or RNA sequence on a chromosome or section of tissue (in-situ) fixed on a slide. FISH profiling is less time-consuming than conventional approaches and assists in easy chromosomal microdeletion, amplification, and translocation. Mass spectrometry-based cancer/tumor profiling is increasingly used in cancer research to detect subtle changes in proteome and metabolome. In contrast, microarrays are widely used to understand cancer cells' genetic and epigenetic makeup, and they are utilized to identify small genetic changes in tumor cells. The development of next-generation sequencing (NGS) helps in effectively exploring genetic alterations in various cancers and identifying several genetic or epigenetic variants to develop new biomarkers for early diagnosis of the disease. Polymerase chain reaction (PCR) is used to look for specific changes in a gene or chromosome, which helps find and diagnose a genetic condition or a disease, such as cancer. Moreover, technological advances in imaging and biochemical processes that allow earlier detection of a metastatic lesion could yield higher success rates in cancer therapy.

Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation

Genomic biomarkers can be termed as the measurement of the expression of a gene, the gene function, or the gene regulation, and testing can determine whether someone's cancer has an estimated glomerular filtration rate (EGFR) gene mutation that can be treated with an EGFR inhibitor and also helps study a new cancer treatment in a clinical trial. An ideal cancer biomarker can be a protein or protein fragment that is easy to detect in the patient's blood or urine except for a healthy patient. In addition, there are many cancer biomarkers, and they separately work within the body and react differently to treatments. These cancer biomarkers can also include gene mutations (changes), gene rearrangements, extra copies of genes, missing genes, and several other molecules.

Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification

Cancer/tumor profiling has become an integral part of disease management on multiple levels for breast cancer. Genetic testing identifies hereditary cancer syndromes in patients with a family history of malignancies and contributes to successful breast cancer prevention. Molecular profiling of colorectal cancer (CRC) has the advantage of providing essential information on the pathogenesis of cancer and also about the targeted therapy. The landscape of metastatic CRC (mCRC) treatment is changing with an understanding of its heterogeneity and molecular blueprint, although chemotherapy remains the backbone of treatment. Common genetic mutations in lung cancer, such as estimated glomerular filtration rate (EGFR), RET, MET, BRAF, and anaplastic lymphoma kinase (ALK), can be detected, which leads to offering targeted therapy to the patient. Molecular predictive tests based on gene expression profiling (GEP) of cutaneous melanoma (CM) are susceptible and have the potential to predict biological behavior. Moreover, cancer/tumor profiling of prostate cancer has more recently emerged as a reliable method for predictive modeling and clinical risk stratification. Integrative genomic profiling of prostate tumors has provided comprehensive information and novel discoveries that improve understanding of the disease in the new era of precision medicine.

Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time

Cancer/tumor profiling has significantly advanced clinical oncology by identifying therapeutic targets and molecular biomarkers, guiding the personalization of cancer treatment with remarkably improved outcomes for numerous common and rare tumor entities. Cancer/tumor profiling is normally used in developing precision medicine that suits a patient's genetic makeup to improve healing and recovery time. The upgradation of biomarker discovery and development with the application of new and complex technologies and more clinical applications of biomarkers improves diagnosis, prognosis, and disease monitoring. Researchers are touting more precision-based and targeted techniques to streamline cancer treatment, which propels rapid diagnostics providers to seek highly sophisticated cancer profiling approaches. Genome-based prognostic biomarkers are used in the prognosis of several cancer types at clinical stages and also help develop drugs and therapies. Cancer/tumor profiling is also helpful in cancer screening and can help in early detection, management, and, potentially, curing cancer. In addition, cancer/tumor profiling offers the sensitive and accurate detection of biomarkers and has a reliable approach for noninvasive disease diagnosis and treatment response monitoring.

Regional Insights

Cancer/tumor profiling market landscape in North America, the EU, GCC, and developed countries across the Asia-Pacific region are highly advanced due to prominent market players and well-established regulatory frameworks and initiatives launched by the governments to reduce cancer burden while improving patient care. Cancer profiling is gradually gaining prominence in developing economies worldwide as investments in cancer diagnostics continue to rise. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer profiling. Northern and Western European countries observe considerably high use and availability of biomarker testing procedures, refiecting their higher investment in healthcare. Market players across countries are collaborating with technology providers in the United States and European countries and each other to contribute to deploying the advancement in cancer diagnosis, profiling, and treatment procedures. Furthermore, the ongoing campaigns and cancer awareness programs have highlighted the need for cancer/tumor profiling in Asian countries.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer/Tumor Profiling Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer/Tumor Profiling Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include 4basecare Onco Solutions Private Limited, ACT Genomics Co., Ltd. by Prenetics Global Limited, Agendia, Inc., Agilent Technologies, Inc., BostonGene Corporation, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENINUS Inc., Genomic Life, GenScript Biotech Corporation, Guardant Health, Inc., Hologic, Inc., HTG Molecular Diagnostics, Inc., Illumina, Inc., IMBdx, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Merck KGaA, NanoString Technologies, Inc., Neogenomics, Inc., Nonacus Limited, OncoDNA S.A., Oncompass Medicine Hungary Kft., Paragon Genomics, Inc., Personalis, Inc., Perthera, Inc., Predictive Oncology Inc., Strand Life Sciences, Sysmex Corporation, Takara Bio Inc., Tempus Labs Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Immunoassays
    • In-Situ Hybridization
    • Mass Spectrometry
    • Microarrays
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Biomarker Type
    • Genomic Biomarker
    • Protein Biomarker
  • Cancer Type
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Melanoma Cancer
    • Prostate Cancer
  • Application
    • Biomarker Discovery
    • Clinical Application
    • Diagnostics
    • Personalized Medicine
    • Prognostics
    • Research
    • Screening
    • Treatment & Monitoring
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cancer/Tumor Profiling Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer/Tumor Profiling Market?

3. What are the technology trends and regulatory frameworks in the Cancer/Tumor Profiling Market?

4. What is the market share of the leading vendors in the Cancer/Tumor Profiling Market?

5. Which modes and strategic moves are suitable for entering the Cancer/Tumor Profiling Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
      • 5.1.1.2. Availability of government and global organizations' initiatives for devising cancer diagnosing methods
      • 5.1.1.3. Surging preference for personalized medicines for cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
      • 5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
    • 5.1.4. Challenges
      • 5.1.4.1. Low biomarker discovery-to-approval ratio
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
    • 5.2.2. Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
    • 5.2.3. Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
    • 5.2.4. Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
  • 5.3. Market Trend Analysis
    • 5.3.1. Government initiatives for cancer diagnostics with rapid advancements in cancer/tumor profiling solutions
    • 5.3.2. Rising cancer prevalence with evolving cancer research initiatives enhancing the need for novel cancer/tumor profiling in the APAC region
    • 5.3.3. Increasing adoption of precision medicines and genetic profiling solutions to overcome the cancer burden across EMEA region
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis

6. Cancer/Tumor Profiling Market, by Technology

  • 6.1. Introduction
  • 6.2. Immunoassays
  • 6.3. In-Situ Hybridization
  • 6.4. Mass Spectrometry
  • 6.5. Microarrays
  • 6.6. Next-Generation Sequencing
  • 6.7. Polymerase Chain Reaction

7. Cancer/Tumor Profiling Market, by Biomarker Type

  • 7.1. Introduction
  • 7.2. Genomic Biomarker
  • 7.3. Protein Biomarker

8. Cancer/Tumor Profiling Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Colorectal Cancer
  • 8.4. Lung Cancer
  • 8.5. Melanoma Cancer
  • 8.6. Prostate Cancer

9. Cancer/Tumor Profiling Market, by Application

  • 9.1. Introduction
  • 9.2. Biomarker Discovery
  • 9.3. Clinical Application
  • 9.4. Diagnostics
  • 9.5. Personalized Medicine
  • 9.6. Prognostics
  • 9.7. Research
  • 9.8. Screening
  • 9.9. Treatment & Monitoring

10. Americas Cancer/Tumor Profiling Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer/Tumor Profiling Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer/Tumor Profiling Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers
    • 13.3.2. Sophia Genetics, Agilent Partner on Cancer Analysis Product
    • 13.3.3. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
    • 13.3.4. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
    • 13.3.5. Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
    • 13.3.6. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
    • 13.3.7. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
    • 13.3.8. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
    • 13.3.9. Prenetics Acquires ACT Genomics
    • 13.3.10. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
    • 13.3.11. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CANCER/TUMOR PROFILING MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER/TUMOR PROFILING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CANCER/TUMOR PROFILING MARKET DYNAMICS
  • FIGURE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER/TUMOR PROFILING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 120. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 128. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 129. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 136. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 137. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 142. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 143. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 144. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 145. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 152. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 153. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 158. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 159. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 160. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 161. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 168. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 176. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 177. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 184. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 192. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 193. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 200. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 201. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 206. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 207. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 208. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 209. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 225. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 226. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 227. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 234. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 235. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 240. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 241. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 242. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 243. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 248. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 249. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 250. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 251. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 258. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 259. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 264. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 265. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 266. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 267. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 274. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 275. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 280. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 281. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 282. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 283. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 288. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 289. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 290. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 291. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 296. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 297. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 298. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 299. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 304. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 305. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 306. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 307. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 308. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 309. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 312. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 313. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 314. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 315. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 320. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 321. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 322. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 323. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 328. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 329. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 330. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 331. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 332. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 333. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 336. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE,